Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T17:22:12.685Z.
Consensus retrieved: 2026-10-06T12:54:11.495Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T17:22:12.685Z.
Quote observation: 2026-10-06T17:20:07.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 2eba736d2827de544c9f141b3fafa3dea8ffa5f0a614b8c2b2ac1915a5af89f6
Forward PE Ratio (N/A) = Dated Quote Price ($1.37) / Consensus Forward EPS ($-0.52)
FORWARD PE RATIO
N/A
Century Therapeutics, Inc.
Market Cap
$248.15M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Century Therapeutics, Inc. (IPSC) | $248.15M | N/A |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $248.93M | N/A |
| Quantum-Si incorporated (QSI)vs › | $245.38M | N/A |
| Lifecore Biomedical, Inc. (LFCR)vs › | $242.50M | N/A |
| Q32 Bio Inc. (QTTB)vs › | $242.28M | N/A |
| Greenwich LifeSciences, Inc. (GLSI)vs › | $242.04M | N/A |
| Galectin Therapeutics Inc. (GALT)vs › | $240.38M | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $239.81M | N/A |
| X4 Pharmaceuticals, Inc. (XFOR)vs › | $256.55M | N/A |
| Anika Therapeutics, Inc. (ANIK)vs › | $257.28M | 18.31 |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $1.37, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-0.52 | $-0.52 – $-0.51 | 3 | n/m |
| 2027-12-31 | $-0.45 | $-0.48 – $-0.41 | 3 | n/m |
| 2028-12-31 | $-0.36 | $-0.38 – $-0.34 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
